Table 4.
Comparison between CML-BP as evolution of a chronic phase (secondary BP) and de novo CML-BP.
| Variable | Secondary CML-BP (N = 151) | De novo CML-BP (N = 89) | |
|---|---|---|---|
| Patient-related | |||
| Sex, male, n (%) | 97 (64.2%) | 47 (52.8%) | |
| Age at onset of CML-BP (yrs), median (range) | 49 (18–85) | 48 (20–86) | |
| CML-related | |||
| Morphology of CML-BP, n/N (%) | Myeloid | 75/148 (50.7%) | 42/85 (49.4%) |
| Lymphoid | 46/148 (31.1%) | 25/85 (29.4%) | |
| Mixed | 5/148 (3.4%) | 5/85 (5.9%) | |
| Megakaryoblastic | 1/148 (0.7%) | 2/85 (2.4%) | |
| Unknown | 21/148 (14.2%) | 11/85 (12.9%) | |
| Not reported | 3 (2.0%) | 4 (4.5%) | |
| Additional chromosomal abnormalities (ACAs), yes, n/N(%) | Complex karyotype | 38/101 (37.6%) | 14/73 (19.2%) |
| Chr. 3q26.2 rearrangements | 6/101 (5.9%) | 3/73 (4.1%) | |
| −7/−7q | 12/101 (11.9%) | 0/73 (0%) | |
| +8 | 23/101 (22.8%) | 0/73 (0%) | |
| others | 41/101 (40.6%) | 22/73 (30.1%) | |
| Not reported | 50 (33.1%) | 16 (18.0%) | |
| High risk ACAsa, yes, n/N(%) | 56/101 (55.4%) | 16/73 (21.9%) | |
| Not reported | 50 (33.1%) | 16 (18.0%) | |
| Mutations in BCR::ABL1, yes, n/N(%) | 39/104 (37.5%) | 7/62 (11.3%) | |
| Not reported | 47 (31.1%) | 27 (30.3%) | |
| CNS involvement, yes, n/N(%) | 10/133 (7.5%) | 11/81 (13.6%) | |
| Not reported | 18 (11.9%) | 8 (9.0%) | |
| Extramedullary disease, yes, n/N(%) | 27/136 (19.9%) | 16/84 (19.0%) | |
| Not reported | 15 (9.9%) | 5 (5.6%) | |
CML-BP chronic myeloid leukemia blast phase, M male, F female, yrs years, chr. chromosome, CNS central nervous system.
aHigh risk ACAs: +8, +Ph, i[17q], +17, +19, +21, 11q23 and 3q26.2 rearrangements, −7/7q abnormalities, complex karyotype.